Pharma BD Deal Intelligence
Third Wave's Cervista platform got its FDA approvals, then got written down and cannibalized by Hologic's own competing Gen-Probe/Aptima technology within seven years.
Full analysis, sources & comparables →GenomeWeb framed the transaction as Hologic's entry into molecular diagnostics on the back of Third Wave's Invader chemistry and pending HPV PMAs, positioning…
Modern Healthcare reported the acquisition as a strategic bid for the high-growth molecular diagnostics segment, noting the deal would be modestly dilutive in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$11.25/share cash; HPV testing, Invader chemistry; closed July 24 2008
Third Wave's Cervista platform got its FDA approvals, then got written down and cannibalized by Hologic's own competing Gen-Probe/Aptima technology within seven years.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hologic, Inc. / Third Wave Technologies, Inc. (this deal) | 2008 | $580M | 36 |
| Hologic, Inc. / Gen-Probe Incorporated | 2012 | $3.8B | 78 |
| Hologic, Inc. / Cynosure, Inc. | 2017 | $1.6B | 12 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2008 deals · Hologic, Inc. deals · Oncology deals